Renal cell carcinoma (RCC) is a common form of kidney cancer and accounts for the majority of cancers found in the kidney.

Despite major advances in the field of oncology, this disease remains challenging due to its biological heterogeneity, the late-stage diagnosis in many patients, and complex molecular drivers.

As a result, renal cell carcinoma research depends heavily on access to well-annotated biospecimens.

At Bay Biosciences, we recognize that reliable biospecimens are the foundation of credible research and provide high-quality renal cell carcinoma samples, tissue, serum, and plasma to support meaningful research.

Tissue Samples, Serum, and Plasma in Renal Cell Carcinoma Research

Understanding Renal Cell Carcinoma

Renal cell carcinoma originates in the lining of the proximal tubules within the kidney. Among its histological subtypes, clear cell renal cell carcinoma (ccRCC) is the most prevalent and accounts for approximately 85% of RCC cases.

The “clear cell” appearance results from lipid and glycogen accumulation in tumor cells, which creates a pale cytoplasm under microscopic examination.

Other subtypes include papillary RCC and chromophobe RCC. Both of these have distinct genetic profiles and clinical behaviors.

Renal Cell Carcinoma Symptoms and Clinical Presentation

One of the major challenges in renal cell carcinoma research is that early-stage RCC often presents without noticeable symptoms.

When symptoms do occur, they may include:

Many cases are discovered incidentally during imaging studies for unrelated conditions.

Because renal cell carcinoma symptoms can be subtle or absent in early stages, biomarker discovery using serum and plasma has become a significant research focus.

Causes of Renal Cell Carcinoma

The causes of renal cell carcinoma include a mix of environmental and genetic factors.

Known risk factors include:

Tests Used to Diagnose Renal Cell Carcinoma

Healthcare providers rely primarily on advanced imaging techniques to detect renal cell carcinoma (RCC), evaluate tumor characteristics, and guide treatment planning.

These diagnostic tools help assess the size, location, and potential spread of kidney tumors.

1. Ultrasound

Ultrasound is used to evaluate a suspected kidney mass. This technique sends high-frequency sound waves through body tissues to generate real-time images on a monitor. By analyzing these images, healthcare professionals can determine whether a mass contains fluid, which usually suggests a benign cyst, or solid tissue, which raises suspicion for malignancy.

2. Computed Tomography (CT) Scan

Physicians also frequently use CT scans to obtain highly detailed cross-sectional images of the kidneys and surrounding structures. In most cases, patients receive intravenous contrast dye before or during the scan, which helps clinicians assess tumor size, vascular involvement, and possible metastasis.

3. Magnetic Resonance Imaging (MRI)

Providers may recommend an MRI when a patient cannot undergo a CT scan, such as in cases of contrast allergy or impaired kidney function. MRI technology uses magnetic fields, radio waves, and computer processing to produce detailed anatomical images. Clinicians also rely on MRI when ultrasound and CT findings remain inconclusive or when further evaluation of vascular structures is needed. 

Role of Biopsy in RCC

Although physicians commonly perform biopsies to confirm many types of cancer, they do not routinely use this approach for renal cell carcinoma because, in RCC cases, the procedure can carry risks, including bleeding or kidney damage.

Is ccRCC Hereditary?

A frequently asked question in both clinical and research contexts is: Is ccRCC hereditary?

Most cases of clear cell RCC are sporadic. However, a small percentage are linked to inherited syndromes, including von Hippel–Lindau disease, hereditary papillary RCC, and Birt-Hogg-Dubé syndrome.

These hereditary forms provide valuable research opportunities because germline mutations help clarify molecular drivers of tumor formation.

For researchers investigating hereditary risk, matched germline DNA samples alongside tumor tissue are essential to differentiate inherited mutations from somatic alterations.

The Role of Tumor Tissue in Renal Cell Carcinoma Research

Tumor tissue remains the gold standard in oncology research.

In RCC, tissue samples provide critical insights into:

  • Histological subtype classification
  • Tumor grade and stage
  • Molecular mutations
  • Immune cell infiltration
  • Angiogenic signaling pathways
  • Tumor heterogeneity

Serum Samples in Renal Cell Carcinoma Research

Serum is obtained after blood coagulation and removal of clotting factors. In renal cell carcinoma research, serum plays a crucial role in:

  • Biomarker discovery
  • Cytokine profiling
  • Circulating tumor protein analysis
  • Autoantibody detection

Researchers analyze serum to identify protein signatures associated with early-stage RCC or metastatic disease. Elevated levels of inflammatory cytokines, angiogenic factors such as VEGF, and tumor-associated antigens may serve as prognostic or predictive biomarkers.

Serum samples are particularly valuable for longitudinal studies, where investigators monitor biomarker changes over time to assess disease progression or therapeutic response.

Plasma Samples in Renal Cell Carcinoma Research

Plasma differs from serum in that it is collected using anticoagulants and retains clotting factors.

This sample has become increasingly important in RCC research because it supports liquid biopsy approaches.

1. Circulating Tumor DNA (ctDNA)

Plasma allows for the detection of circulating tumor DNA, which provides less invasive insight into tumor mutation profiles. Researchers can track emerging mutations associated with therapy resistance without repeated invasive biopsies.

2. Circulating Tumor Cells (CTCs)

Although less common in RCC compared to other cancers, circulating tumor cells can still be studied through plasma-based methods.

3. Extracellular Vesicles and MicroRNAs

Plasma contains extracellular vesicles and tumor-derived microRNAs that may function as diagnostic or prognostic biomarkers.

Treatment and Research Applications

The treatment of renal cell carcinoma has evolved significantly over the past two decades.

Today, treatment options include:

  • Surgical resection
  • Targeted therapies (e.g., VEGF inhibitors, mTOR inhibitors)
  • Immune checkpoint inhibitors
  • Combination immunotherapy regimens

Renal cell carcinoma samples continue to help in evaluating predictive biomarkers that determine which patients will respond best to specific treatments.

Supporting Your Research With Bay Biosciences

Renal cell carcinoma research depends on accurate data and reliable biospecimens.

Researchers need high-quality renal cell carcinoma samples to study tumor biology, evaluate biomarkers, test therapeutic responses, and generate reproducible findings.

The integrity and traceability of these samples directly influence the credibility of scientific outcomes and clinical translation.

At Bay Biosciences, we provide access to ethically sourced, high-quality biospecimens, including:

Repositories and biobanks like ours that properly catalog and preserve samples ensure that the right specimens with detailed clinical annotations are accessible for meaningful research.

You can learn more about our quality assurance and quality control standards on our website.

If you have specific project requirements, need custom collection protocols, or have questions regarding sample availability, please don’t hesitate to reach out to us!